Ipsen S.A.
65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 5,325
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. David Loew | MD, CEO & Director | 2.11M | 無 | 1967 |
| Mr. Aymeric Le Chatelier | Executive VP & CFO | 731.25k | 無 | 1969 |
| Dr. Aidan Murphy Ph.D. | Executive VP and Head of Technical Operations | 無 | 無 | 1966 |
| Mr. Craig Marks | Vice-President of Investor Relations | 無 | 無 | 無 |
| Mr. Francois Garnier | Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer | 無 | 無 | 1962 |
| Ms. Gwenan White | Executive VP and Head of Communications, Public Affairs & Sustainability | 無 | 無 | 無 |
| Mr. Regis Mulot | Executive VP & Chief Human Resources Officer | 無 | 無 | 1966 |
| Ms. Dominique Bery | Head of Nordics & Baltics | 無 | 無 | 1971 |
| Mr. Bartosz Bednarz D.D.S. | Executive VP and Head of Global Product & Portfolio Strategy | 無 | 無 | 無 |
| Mr. Philippe Lopes-Fernandes CBO | Executive VP & Chief Business Officer | 無 | 無 | 無 |
描述
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
公司管治
截至 2024年5月1日 止，Ipsen S.A. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：7；股東權利：7；現金賠償：7。
